ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors)

Clinical Microbiology and Infection

Volumn 24, Issue , 2018, Pages S21-S40

  Winthrop, K L ^a   Mariette, X ^b   Silva, J T ^c   Benamu, E ^d   Calabrese, L H ^e   Dumusc, A ^f   Smolen, J S ^g   Aguado, J M ^h,i   Fernandez Ruiz M ^h,i  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c Badajoz University Hospital   (Spain)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h Universidad Complutense   (Spain)

ⁱ INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Anakinra; Brodalumab; Canakinumab; Eculizumab; Infection; Ixekizumab; Prevention; Rilonacept; Secukinumab; Tocilizumab

Indexed keywords

ANAKINRA; BIOLOGICAL PRODUCT; BRODALUMAB; CANAKINUMAB; COMPLEMENT COMPONENT C5; COMPLEMENT FACTOR; ECULIZUMAB; GEVOKIZUMAB; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN DERIVATIVE; IXEKIZUMAB; MEPOLIZUMAB; OMALIZUMAB; RILONACEPT; SECUKINUMAB; SILTUXIMAB; TOCILIZUMAB; USTEKINUMAB; COMPLEMENT; DERMATOLOGICAL AGENT; MENINGOCOCCUS VACCINE; MONOCLONAL ANTIBODY;

BIOLOGICAL THERAPY; CHEMOPROPHYLAXIS; DRUG SAFETY; HIGH RISK BEHAVIOR; HUMAN; INFECTION RISK; LATENT TUBERCULOSIS; MUCOCUTANEOUS CANDIDIASIS; NEISSERIA; PRIORITY JOURNAL; REVIEW; STRONGYLOIDES STERCORALIS; VACCINATION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); COMMUNICABLE DISEASE; COMMUNICABLE DISEASE CONTROL; CONSENSUS DEVELOPMENT; DRUG EFFECT; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL THERAPY; CLINICAL TRIALS AS TOPIC; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; COMPLEMENT SYSTEM PROTEINS; DERMATOLOGIC AGENTS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULINS; INTERLEUKIN-17; INTERLEUKINS; MENINGOCOCCAL VACCINES; MOLECULAR TARGETED THERAPY;

EID: 85043269426     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2018.02.002     Document Type: Review

References (270)

1. Fernández-Ruiz, M., Meije, T., Manuel, O., Akan, H., Carratalà J., Aguado, J.M., et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (introduction). Clin Microbiol Infect 24 (2018), S2–S9.
2. Hahn, M., Frey, S., Hueber, A.J., The novel interleukin-1 cytokine family members in inflammatory diseases. Curr Opin Rheumatol 29 (2017), 208–213.
3. Kahlenberg, J.M., Anti-inflammatory panacea? The expanding therapeutics of interleukin-1 blockade. Curr Opin Rheumatol 28 (2016), 197–203.
4. Satoh, T., Otsuka, A., Contassot, E., French, L.E., The inflammasome and IL-1β: implications for the treatment of inflammatory diseases. Immunotherapy 7 (2015), 243–254.
5. Vitale, A., Insalaco, A., Sfriso, P., Lopalco, G., Emmi, G., Cattalini, M., et al. A Snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study. Front Pharmacol, 7, 2016, 380.
6. Ottaviani, S., Brunier, L., Sibilia, J., Maurier, F., Ardizzone, M., Wendling, D., et al. Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature. Joint, Bone, Spine Rev Rhumatisme 80 (2013), 178–182.
7. Cantarini, L., Lopalco, G., Caso, F., Costa, L., Iannone, F., Lapadula, G., et al. Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease. Autoimmun Rev 14 (2015), 1–9.
8. Jain, S., Thongprayoon, C., Espinosa, R.E., Hayes, S.N., Klarich, K.W., Cooper, L.T., et al. Effectiveness and safety of anakinra for management of refractory pericarditis. Am J Cardiol 116 (2015), 1277–1279.
9. Cugno, M., Borghi, A., Marzano, A.V., PAPA, PASH and PAPASH syndromes: pathophysiology, presentation and treatment. Am J Clin Dermatol 18 (2017), 555–562.
10. Ridker, P.M., Everett, B.M., Thuren, T., MacFadyen, J.G., Chang, W.H., Ballantyne, C., et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377 (2017), 1119–1131.
11. Dinarello, C.A., van der Meer, J.W.M., Treating inflammation by blocking interleukin-1 in humans. Semin Immunol 25 (2013), 469–484.
12. Martinon, F., Burns, K., Tschopp, J., The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol Cell 10 (2002), 417–426.
13. Man, S.M., Karki, R., Kanneganti, T.D., Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. Immunol Rev 277 (2017), 61–75.
14. Poltorak, A., He, X., Smirnova, I., Liu, M.Y., Van Huffel, C., Du, X., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282 (1998), 2085–2088.
15. Chen, I.-Y., Ichinohe, T., Response of host inflammasomes to viral infection. Trends Microbiol 23 (2015), 55–63.
16. Coutermarsh-Ott, S., Eden, K., Allen, I.C., Beyond the inflammasome: regulatory NOD-like receptor modulation of the host immune response following virus exposure. J Gen Virol 97 (2016), 825–838.
17. Guler, R., Parihar, S.P., Spohn, G., Johansen, P., Brombacher, F., Bachmann, M.F., Blocking IL-1α but not IL-1β increases susceptibility to chronic Mycobacterium tuberculosis infection in mice. Vaccine 29 (2011), 1339–1346.
18. Hossain, M.M., Norazmi, M.N., Pattern recognition receptors and cytokines in Mycobacterium tuberculosis infection–the double-edged sword?. Biomed Res Int, 2013, 2013, 179174.
19. Bellamy, R., Ruwende, C., Corrah, T., McAdam, K.P., Whittle, H.C., Hill, A.V., Assessment of the interleukin 1 gene cluster and other candidate gene polymorphisms in host susceptibility to tuberculosis. Tubercle Lung Dis 79 (1998), 83–89.
20. Motsinger-Reif, A.A., Antas, P.R., Oki, N.O., Levy, S., Holland, S.M., Sterling, T.R., Polymorphisms in IL-1β vitamin D receptor Fok1, and Toll-like receptor 2 are associated with extrapulmonary tuberculosis. BMC Med Genet, 11, 2010, 37.
21. Wojtowicz, A., Gresnigt, M.S., Lecompte, T., Bibert, S., Manuel, O., Joosten, L.A., et al. IL1B and DEFB1 polymorphisms increase susceptibility to invasive mold infection after solid-organ transplantation. J Infect Dis 211 (2015), 1646–1657.
22. Terkeltaub, Ra, Schumacher, H.R., Carter, J.D., Baraf, H.S.B., Evans, R.R., Wang, J., et al. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther, 15, 2013, R25.
23. So, A., De Meulemeester, M., Pikhlak, A., Richard, D., Yücel, A.E., Murphy, V., et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 62 (2010), 3064–3076.
24. So, A., De Smedt, T., Revaz, S., Tschopp, J., A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther, 9, 2007, R28.
25. Nuki, G., Bresnihan, B., Bear, M.B., McCabe, D., Investigators EGOC. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (2002), 2838–2846.
26. Fleischmann, R.M., Schechtman, J., Bennett, R., Handel, M.L., Burmester, G.-R., Tesser, J., et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum 48 (2003), 927–934.
27. Fleischmann, R.M., Tesser, J., Schiff, M.H., Schechtman, J., Burmester, G.-R., Bennett, R., et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheumatic Dis 65 (2006), 1006–1012.
28. Cohen, S., Hurd, E., Cush, J., Schiff, M., Weinblatt, M.E., Moreland, L.W., et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (2002), 614–624.
29. Genovese, M.C., Cohen, S., Moreland, L., Lium, D., Robbins, S., Newmark, R., et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50 (2004), 1412–1419.
30. den Broeder, A.A., de Jong, E., Franssen, M.J.A.M., Jeurissen, M.E.C., Flendrie, M., van den Hoogen, F.H.J., Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis 65 (2006), 760–762.
31. Settas, L.D., Tsimirikas, G., Vosvotekas, G., Triantafyllidou, E., Nicolaides, P., Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra). J Clin Rheumatol 13 (2007), 219–220.
32. Migkos, M.P., Somarakis, G.A., Markatseli, T.E., Matthaiou, M., Kosta, P., Voulgari, P.V., et al. Tuberculous pyomyositis in a rheumatoid arthritis patient treated with anakinra. Clin Exp Rheumatol 33 (2015), 734–736.
33. Schlesinger, N., Alten, R.E., Bardin, T., Schumacher, H.R., Bloch, M., Gimona, A., et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 71 (2012), 1839–1848.
34. Schlesinger, N., Mysler, E., Lin, H.-Y., De Meulemeester, M., Rovensky, J., Arulmani, U., et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 70 (2011), 1264–1271.
35. Sundy, J.S., Schumacher, H.R., Kivitz, A., Weinstein, S.P., Wu, R., King-Davis, S., et al. Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. J Rheumatol 41 (2014), 1703–1711.
36. Lachmann, H.J., Kone-Paut, I., Kuemmerle-Deschner, J.B., Leslie, K.S., Hachulla, E., Quartier, P., et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360 (2009), 2416–2425.
37. Goldbach-Mansky, R., Dailey, N.J., Canna, S.W., Gelabert, A., Jones, J., Rubin, B.I., et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N Engl J Med 355 (2006), 581–592.
38. Neven, B., Marvillet, I., Terrada, C., Ferster, A., Boddaert, N., Couloignier, V., et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 62 (2010), 258–267.
39. Kuemmerle-Deschner, J.B., Tyrrell, P.N., Koetter, I., Wittkowski, H., Bialkowski, A., Tzaribachev, N., et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle–Wells syndrome. Arthritis Rheum 63 (2011), 840–849.
40. Sibley, C.H., Plass, N., Snow, J., Wiggs, E.A., Brewer, C.C., King, K.A., et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum 64 (2012), 2375–2386.
41. Kullenberg, Tn, Löfqvist, M., Leinonen, M., Goldbach-Mansky, R., Olivecrona, H., Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes. Rheumatology (Oxf) 55 (2016), 1499–1506.
42. Brucato, A., Imazio, M., Gattorno, M., Lazaros, G., Maestroni, S., Carraro, M., et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP Randomized Clinical Trial. JAMA 316 (2016), 1906–1912.
43. Hoffman, H.M., Throne, M.L., Amar, N.J., Cartwright, R.C., Kivitz, A.J., Soo, Y., et al. Long-term efficacy and safety profile of rilonacept in the treatment of cryopyrin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther 34 (2012), 2091–2103.
44. Cavalli, G., Franchini, S., Aiello, P., Guglielmi, B., Berti, A., Campochiaro, C., et al. Efficacy and safety of biological agents in adult-onset Still's disease. Scand J Rheumatol 44 (2015), 309–314.
45. Ghosh, P., Cho, M., Rawat, G., Simkin, P.A., Gardner, G.C., Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res 65 (2013), 1381–1384.
46. Ruperto, N., Brunner, H.I., Quartier, P., Constantin, T., Wulffraat, N., Horneff, G., et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 367 (2012), 2396–2406.
47. Lequerré T., Quartier, P., Rosellini, D., Alaoui, F., De Bandt, M., Mejjad, O., et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67 (2008), 302–308.
48. Grayson, P.C., Yazici, Y., Merideth, M., Sen, H.N., Davis, M., Novakovich, E., et al. Treatment of mucocutaneous manifestations in Behçet's disease with anakinra: a pilot open-label study. Arthritis Res Ther, 19, 2017, 69.
49. Emmi, G., Talarico, R., Lopalco, G., Cimaz, R., Cantini, F., Viapiana, O., et al. Efficacy and safety profile of anti-interleukin-1 treatment in Beh軻t's disease: a multicenter retrospective study. Clin Rheumatol 35 (2016), 1281–1286.
50. Lopalco, G., Vitale, A., Iannone, F., Cantarini, L., Anakinra long-term efficacy and safety in the management of Schnitzler's syndrome and latent tuberculosis infection. Clin Exp Rheumatol, 34, 2016, 353.
51. Emmi, G., Silvestri, E., Squatrito, D., Vitale, A., Bacherini, D., Vannozzi, L., et al. Long-term efficacy and safety of anakinra in a patient with Behçet's disease and concomitant tuberculosis infection. Int J Dermatol 56 (2017), 218–220.
52. Bilginer, Y., Ayaz, N.A., Ozen, S., Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease. Clin Rheumatol 29 (2010), 209–210.
53. Chioato, A., Noseda, E., Felix, S.D., Stevens, M., Del Giudice, G., Fitoussi, S., et al. Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 β-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study. Clin Vaccine Immunol 17 (2010), 1952–1957.
54. Rubin, L.G., Levin, M.J., Ljungman, P., Davies, E.G., Avery, R., Tomblyn, M., et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58 (2014), e44–100.
55. Kim, D.K., Riley, L.E., Harriman, K.H., Hunter, P., Bridges, C.B., Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older – United States. MMWR Morb Mortal Wkly Rep 2017:66 (2017), 136–138.
56. Varricchi, G., Bagnasco, D., Borriello, F., Heffler, E., Canonica, G.W., Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs. Curr Opin Allergy Clin Immunol 16 (2016), 186–200.
57. Kusano, S., Kukimoto-Niino, M., Hino, N., Ohsawa, N., Ikutani, M., Takaki, S., et al. Structural basis of interleukin-5 dimer recognition by its α receptor. Protein Sci 21 (2012), 850–864.
58. Menzella, F., Lusuardi, M., Galeone, C., Taddei, S., Zucchi, L., Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases. J Asthma Allergy 8 (2015), 105–114.
59. Stein, M.L., Villanueva, J.M., Buckmeier, B.K., Yamada, Y., Filipovich, A.H., Assa'ad, A.H., et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol 121 (2008), 1473–1483 83 e1–4.
60. Russell, R., Brightling, C., Mepolizumab for the reduction of exacerbations in severe eosinophilic asthma. Expert Rev Respir Med 10 (2016), 607–617.
61. Wechsler, M.E., Akuthota, P., Jayne, D., Khoury, P., Klion, A., Langford, C.A., et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 376 (2017), 1921–1932.
62. Pavord, I.D., Chanez, P., Criner, G.J., Kerstjens, H.A.M., Korn, S., Lugogo, N., et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med 377 (2017), 1613–1629.
63. Altman, M.C., Lenington, J., Bronson, S., Ayars, A.G., Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract 5 (2017), 1137–1139.
64. Rothenberg, M.E., Klion, A.D., Roufosse, F.E., Kahn, J.E., Weller, P.F., Simon, H.U., et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 358 (2008), 1215–1228.
65. Roufosse, F.E., Kahn, J.E., Gleich, G.J., Schwartz, L.B., Singh, A.D., Rosenwasser, L.J., et al. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol 131 (2013), 461–467 e1–5.
66. Oldhoff, J.M., Darsow, U., Werfel, T., Katzer, K., Wulf, A., Laifaoui, J., et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 60 (2005), 693–696.
67. Bachert, C., Sousa, A.R., Lund, V.J., Scadding, G.K., Gevaert, P., Nasser, S., et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol 140 (2017), 1024–1031.
68. Assa'ad, A.H., Gupta, S.K., Collins, M.H., Thomson, M., Heath, A.T., Smith, D.A., et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 141 (2011), 1593–1604.
69. Maspero, J., Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects. Ther Adv Respir Dis 11 (2017), 311–325.
70. Nutman, T.B., Evaluation and differential diagnosis of marked, persistent eosinophilia. Immunol Allergy Clin North Am 27 (2007), 529–549.
71. Finkelman, F.D., Shea-Donohue, T., Morris, S.C., Gildea, L., Strait, R., Madden, K.B., et al. Interleukin-4- and interleukin-13-mediated host protection against intestinal nematode parasites. Immunol Rev 201 (2004), 139–155.
72. Santiago, H.C., Nutman, T.B., Human helminths and allergic disease: the hygiene hypothesis and beyond. Am J Trop Med Hyg 95 (2016), 746–753.
73. Haldar, P., Brightling, C.E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360 (2009), 973–984.
74. Ortega, H.G., Liu, M.C., Pavord, I.D., Brusselle, G.G., FitzGerald, J.M., Chetta, A., et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371 (2014), 1198–1207.
75. Bel, E.H., Wenzel, S.E., Thompson, P.J., Prazma, C.M., Keene, O.N., Yancey, S.W., et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371 (2014), 1189–1197.
76. Shimoda, T., Odajima, H., Okamasa, A., Kawase, M., Komatsubara, M., Mayer, B., et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergol Int 66 (2017), 445–451.
77. Liu, Y., Zhang, S., Li, D.W., Jiang, S.J., Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. PLoS One, 8, 2013, e59872.
78. Lugogo, N., Domingo, C., Chanez, P., Leigh, R., Gilson, M.J., Price, R.G., et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther 38 (2016), 2058–2070 e1.
79. Cockle, S.M., Stynes, G., Gunsoy, N.B., Parks, D., Alfonso-Cristancho, R., Wex, J., et al. Comparative effectiveness of mepolizumab and omalizumab in severe asthma: an indirect treatment comparison. Respir Med 123 (2017), 140–148.
80. Castro, M., Zangrilli, J., Wechsler, M.E., Bateman, E.D., Brusselle, G.G., Bardin, P., et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 3 (2015), 355–366.
81. Corren, J., Weinstein, S., Janka, L., Zangrilli, J., Garin, M., Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest 150 (2016), 799–810.
82. Bjermer, L., Lemiere, C., Maspero, J., Weiss, S., Zangrilli, J., Germinaro, M., Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest 150 (2016), 789–798.
83. Wang, F.P., Liu, T., Lan, Z., Li, S.Y., Mao, H., Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a systematic review and meta-analysis. PLoS One, 11, 2016 e0166833.
84. Lim, H.F., Nair, P., Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma. Expert Rev Respir Med 9 (2015), 135–142.
85. Calabrese, L.H., Rose-John, S., IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol 10 (2014), 720–727.
86. Stone, J.H., Tuckwell, K., Dimonaco, S., Klearman, M., Aringer, M., Blockmans, D., et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med 377 (2017), 317–328.
87. van Rhee, F., Wong, R.S., Munshi, N., Rossi, J.F., Ke, X.Y., Fossa, A., et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 15 (2014), 966–974.
88. Schiff, M.H., Kremer, J.M., Jahreis, A., Vernon, E., Isaacs, J.D., van Vollenhoven, R.F., Integrated safety in tocilizumab clinical trials. Arthritis Res Ther, 13, 2011, R141.
89. Rose-John, S., Winthrop, K., Calabrese, L., The role of IL-6 in host defense against infections: immunobiology and clinical implications. Nature Rev Rheumatol 13 (2017), 399–409.
90. Jones, G., Ding, C., Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights: Arthritis Musculoskeletal Disorders 3 (2010), 81–89.
91. Liu, X., Jones, G.W., Choy, E.H., Jones, S.A., The biology behind interleukin-6 targeted interventions. Curr Opin Rheumatol 28 (2016), 152–160.
92. Hunter, C.A., Jones, S.A., IL-6 as a keystone cytokine in health and disease. Nat Immunol 16 (2015), 448–457.
93. Vogel, T.P., Milner, J.D., Cooper, M.A., The ying and yang of STAT3 in human disease. J Clin Immunol 35 (2015), 615–623.
94. Burmester, G.R., Lin, Y., Patel, R., van Adelsberg, J., Mangan, E.K., Graham, N.M., et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis 76 (2017), 840–847.
95. Genovese, M.C., Fleischmann, R., Furst, D., Janssen, N., Carter, J., Dasgupta, B., et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis 73 (2014), 1607–1615.
96. Genovese, M.C., Fleischmann, R., Kivitz, A.J., Rell-Bakalarska, M., Martincova, R., Fiore, S., et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol 67 (2015), 1424–1437.
97. Mease, P.J., Gottlieb, A.B., Berman, A., Drescher, E., Xing, J., Wong, R., et al. The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis. Arthritis Rheumatol 68 (2016), 2163–2173.
98. Smolen, J.S., Weinblatt, M.E., Sheng, S., Zhuang, Y., Hsu, B., Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 73 (2014), 1616–1625.
99. Takeuchi, T., Tanaka, Y., Yamanaka, H., Amano, K., Nagamine, R., Park, W., et al. Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: results from a randomized phase II trial. Mod Rheumatol 26 (2016), 15–23.
100. Weinblatt, M.E., Mease, P., Mysler, E., Takeuchi, T., Drescher, E., Berman, A., et al. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. Arthritis Rheumatol 67 (2015), 2591–2600.
101. Bykerk, V.P., Ostor, A.J., Alvaro-Gracia, J., Pavelka, K., Ivorra, J.A., Graninger, W., et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Ann Rheum Dis 71 (2012), 1950–1954.
102. Strand, V., Ahadieh, S., French, J., Geier, J., Krishnaswami, S., Menon, S., et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther, 17, 2015, 362.
103. Iking-Konert, C., von Hinuber, U., Richter, C., Schwenke, H., Gurtler, I., Kastner, P., et al. ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany. Rheumatology (Oxford) 55 (2016), 624–635.
104. Ishiguro, N., Atsumi, T., Harigai, M., Mimori, T., Nishimoto, N., Sumida, T., et al. Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: the FIRST Bio study. Mod Rheumatol 27 (2017), 217–226.
105. Koike, T., Harigai, M., Inokuma, S., Ishiguro, N., Ryu, J., Takeuchi, T., et al. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol 41 (2014), 15–23.
106. Yun, H., Xie, F., Delzell, E., Chen, L., Levitan, E.B., Lewis, J.D., et al. Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. Ann Rheum Dis 74 (2015), 1065–1071.
107. Xie, F., Yun, H., Bernatsky, S., Curtis, J.R., Risk for gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologics. Arthritis Rheumatol 68 (2016), 2612–2617.
108. Yun, H., Xie, F., Delzell, E., Chen, L., Levitan, E.B., Lewis, J.D., et al. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken) 67 (2015), 731–736.
109. Nagashima, T., Maruyama, A., Kamata, Y., Minota, S., Unchanged serum viral load and liver function during tocilizumab treatment in a patient with rheumatoid arthritis and hepatitis C virus infection. Rheumatol Int 32 (2012), 2231–2232.
110. Nagashima, T., Minota, S., Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. Rheumatology (Oxford) 47 (2008), 1838–1840.
111. Tsuboi, H., Tsujii, A., Nampei, A., Yoshihara, H., Kawano, K., Takeuchi, E., et al. A patient with rheumatoid arthritis treated with tocilizumab together with lamivudine prophylaxis after remission of infliximab-reactivated hepatitis B. Mod Rheumatol 21 (2011), 701–705.
112. Nakamura, J., Nagashima, T., Nagatani, K., Yoshio, T., Iwamoto, M., Minota, S., Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int J Rheum Dis 19 (2016), 470–475.
113. Koutsianas, C., Thomas, K., Vassilopoulos, D., Hepatitis B reactivation in rheumatic diseases: screening and prevention. Rheum Dis Clin North Am 43 (2017), 133–149.
114. Barone, M., Notarnicola, A., Lopalco, G., Viggiani, M.T., Sebastiani, F., Covelli, M., et al. Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. Hepatology 62 (2015), 40–46.
115. US Food and Drug Administration. “Stelara” (ustekinumab). Revised: 09/2016. Washington DC: FDA.
116. European Medicines Agency, “Stelara” (ustekinumab). Summary of product characteristics. last revision, November 2016, Janssen-Cilag International NV, Beerse, Belgium.
117. Wohlrab, J., Kreft, B., Treatment of pityriasis rubra pilaris with ustekinumab. Br J Dermatol 163 (2010), 655–656.
118. Cornillier, H., Kervarrec, T., Tabareau-Delalande, F., Mammou, S., Jonville Bera, A.P., Machet, L., Interstitial granulomatous dermatitis occurring in a patient with SAPHO syndrome one month after starting leflunomide, and subsequently disappearing with ustekinumab. Eur J Dermatol 26 (2016), 614–615.
119. Kluger, N., Ustekinumab for pyoderma gangrenosum. Arch Dermatol, 148, 2012, 655 author reply 6.
120. Blok, J.L., Li, K., Brodmerkel, C., Horvatovich, P., Jonkman, M.F., Horvath, B., Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol 174 (2016), 839–846.
121. Langrish, C.L., McKenzie, B.S., Wilson, N.J., de Waal Malefyt, R., Kastelein, R.A., Cua, D.J., IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 202 (2004), 96–105.
122. Cooper, M.A., Fehniger, T.A., Caligiuri, M.A., The biology of human natural killer-cell subsets. Trends Immunol 22 (2001), 633–640.
123. bright natural killer (NK) cells: an important NK cell subset. Immunology 126 (2009), 458–465.
124. Trinchieri, G., Pflanz, S., Kastelein, R.A., The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 19 (2003), 641–644.
125. Bustamante, J., Boisson-Dupuis, S., Abel, L., Casanova, J.L., Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-γ immunity. Semin Immunol 26 (2014), 454–470.
126. de Beaucoudrey, L., Samarina, A., Bustamante, J., Cobat, A., Boisson-Dupuis, S., Feinberg, J., et al. Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore) 89 (2010), 381–402.
127. Aggarwal, S., Ghilardi, N., Xie, M.H., de Sauvage, F.J., Gurney, A.L., Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 278 (2003), 1910–1914.
128. Puel, A., Cypowyj, S., Marodi, L., Abel, L., Picard, C., Casanova, J.L., Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr Opin Allergy Clin Immunol 12 (2012), 616–622.
129. Saunte, D.M., Mrowietz, U., Puig, L., Zachariae, C., Candida infections in psoriasis and psoriatic arthritis patients treated with IL-17 inhibitors and their practical management. Br J Dermatol 177 (2017), 47–62.
130. Leonardi, C.L., Kimball, A.B., Papp, K.A., Yeilding, N., Guzzo, C., Wang, Y., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371 (2008), 1665–1674.
131. Griffiths, C.E., Strober, B.E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 362 (2010), 118–128.
132. Tsai, T.F., Ho, J.C., Song, M., Szapary, P., Guzzo, C., Shen, Y.K., et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 63 (2011), 154–163.
133. Landells, I., Marano, C., Hsu, M.C., Li, S., Zhu, Y., Eichenfield, L.F., et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol 73 (2015), 594–603.
134. Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 373 (2015), 1318–1328.
135. Blauvelt, A., Reich, K., Tsai, T.F., Tyring, S., Vanaclocha, F., Kingo, K., et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol 76 (2017), 60–69 e9.
136. McInnes, I.B., Kavanaugh, A., Gottlieb, A.B., Puig, L., Rahman, P., Ritchlin, C., et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382 (2013), 780–789.
137. Ritchlin, C., Rahman, P., Kavanaugh, A., McInnes, I.B., Puig, L., Li, S., et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 73 (2014), 990–999.
138. Feagan, B.G., Sandborn, W.J., Gasink, C., Jacobstein, D., Lang, Y., Friedman, J.R., et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 375 (2016), 1946–1960.
139. Gordon, K.B., Papp, K.A., Langley, R.G., Ho, V., Kimball, A.B., Guzzo, C., et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol 66 (2012), 742–751.
140. Kalb, R.E., Fiorentino, D.F., Lebwohl, M.G., Toole, J., Poulin, Y., Cohen, A.D., et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol 151 (2015), 961–969.
141. Umezawa, Y., Fukuchi, O., Ito, T., Saeki, H., Nakagawa, H., Risk of herpes zoster in psoriatic patients undergoing biologic treatment. J Dermatol 41 (2014), 168–170.
142. Adelzadeh, L., Jourabchi, N., Wu, J.J., The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions. J Eur Acad Dermatol Venereol 28 (2014), 846–852.
143. Failla, V., Nikkels, A.F., Ustekinumab and herpes zoster. Dermatology 222 (2011), 119–122.
144. Stollberger, C., Finsterer, J., Varicella zoster virus meningitis under ustekinumab because of plaque psoriasis. J Dermatol 44 (2017), 703–705.
145. Chiu, H.Y., Chen, C.H., Wu, M.S., Cheng, Y.P., Tsai, T.F., The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol 169 (2013), 1295–1303.
146. Sanz-Bueno, J., Vanaclocha, F., Garcia-Doval, I., Torrado, R., Carretero, G., Dauden, E., et al. Risk of reactivation of hepatitis b virus infection in psoriasis patients treated with biologics: a retrospective analysis of 20 cases from the BIOBADADERM database. Actas Dermosifiliogr 106 (2015), 477–482.
147. Rothstein, B., Gottlieb, A., Secukinumab for treating plaque psoriasis. Expert Opin Biol Ther 16 (2016), 119–128.
148. Gaffen, S.L., Recent advances in the IL-17 cytokine family. Curr Opin Immunol 23 (2011), 613–619.
149. Girolomoni, G., Mrowietz, U., Paul, C., Psoriasis: rationale for targeting interleukin-17. Br J Dermatol 167 (2012), 717–724.
150. Lubberts, E., The IL-23–IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol 11 (2015), 415–429.
151. Hueber, W., Sands, B.E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P.D., et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61 (2012), 1693–1700.
152. Kaser, A., Not all monoclonals are created equal - lessons from failed drug trials in Crohn's disease. Best Pract Res Clin Gastroenterol 28 (2014), 437–449.
153. Novartis annouces FDA approval for first IL-17A antagonist Cosentyx (TM) (secukinumab) for moderate-to-severe plaque psoriasis (Media Release) 2015 (last accession: 30 June 2017). Available at: https://www.novartis.com/news/media-releases/novartis-announces-fda-approval-first-il-17a-antagonist-cosentyxtm-secukinumab.
154. Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US [Media Release], 2016 (cited 30 June 2017). Available at: https://www.novartis.com/news/media-releases/novartis-receives-two-new-fda-approvals-cosentyx-treat-patients-ankylosing.
155. Kazemi, T., Farahnik, B., Koo, J., Beroukhim, K., Emerging targeted therapies for plaque psoriasis – impact of ixekizumab. Clin Cosmet Investig Dermatol 10 (2017), 133–139.
156. FDA approves new psoriasis drug Taltz (Media Release), 2016 (cited 30 June 2017). Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491872.htm.
157. Galluzzo, M., D'Adamio, S., Bianchi, L., Talamonti, M., Brodalumab for the treatment of psoriasis. Expert Rev Clin Immunol 12 (2016), 1255–1271.
158. FDA approves new psoriasis drug (Media Release), 2017 (cited30 June 2017). Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm541981.htm?source=govdelivery.
159. Blauvelt, A., Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf 15 (2016), 1413–1420.
160. Blauvelt, A., Lebwohl, M.G., Bissonnette, R., IL-23/IL-17A dysfunction phenotypes inform possible clinical effects from anti-IL-17A therapies. J Invest Dermatol 135 (2015), 1946–1953.
161. Ling, Y., Puel, A., IL-17 and infections. Actas Dermosifiliogr 105:Suppl. 1 (2014), 34–40.
162. Kammuller, M., Tsai, T.F., Griffiths, C.E., Kapoor, N., Kolattukudy, P.E., Brees, D., et al. Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clin Transl Immunol, 6, 2017, e152.
163. van de Kerkhof, P.C., Griffiths, C.E., Reich, K., Leonardi, C.L., Blauvelt, A., Tsai, T.F., et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol, 75, 2016 83–98 e4.
164. Mease, P.J., McInnes, I.B., Kirkham, B., Kavanaugh, A., Rahman, P., van der Heijde, D., et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 373 (2015), 1329–1339.
165. Baeten, D., Baraliakos, X., Braun, J., Sieper, J., Emery, P., van der Heijde, D., et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382 (2013), 1705–1713.
166. Farahnik, B., Beroukhim, K., Abrouk, M., Nakamura, M., Zhu, T.H., Singh, R., et al. Brodalumab for the treatment of psoriasis: a review of phase III trials. Dermatol Ther (Heidelb) 6 (2016), 111–124.
167. Attia, A., Abushouk, A.I., Ahmed, H., Gadelkarim, M., Elgebaly, A., Hassan, Z., et al. Safety and efficacy of brodalumab for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis. Clin Drug Investig 37 (2017), 439–451.
168. Papp, K.A., Bachelez, H., Blauvelt, A., Winthrop, K.L., Romiti, R., Ohtsuki, M., et al. Infections from 7 clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis. Br J Dermatol 177 (2017), 1537–1551.
169. Saunte, D.M., Mrowietz, U., Puig, L., Zachariae, C., Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol 177 (2017), 47–62.
170. MacGlashan, D.W. Jr., Bochner, B.S., Adelman, D.C., Jardieu, P.M., Togias, A., McKenzie-White, J., et al. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 158 (1997), 1438–1445.
171. Chanez, P., Contin-Bordes, C., Garcia, G., Verkindre, C., Didier, A., De Blay, F., et al. Omalizumab-induced decrease of FcxiRI expression in patients with severe allergic asthma. Respir Med 104 (2010), 1608–1617.
172. Lin, C.H., Cheng, S.L., A review of omalizumab for the management of severe asthma. Drug Des Devel Ther 10 (2016), 2369–2378.
173. Zuberbier, T., Maurer, M., Omalizumab for the treatment of chronic urticaria. Expert Rev Clin Immunol 11 (2015), 171–180.
174. Lommatzsch, M., Korn, S., Buhl, R., Virchow, J.C., Against all odds: anti-IgE for intrinsic asthma?. Thorax 69 (2014), 94–96.
175. Wang, H.H., Li, Y.C., Huang, Y.C., Efficacy of omalizumab in patients with atopic dermatitis: a systematic review and meta-analysis. J Allergy Clin Immunol 138 (2016), 1719–1722.
176. Homma, T., Kurokawa, M., Matsukura, S., Yamaguchi, M., Adachi, M., Anti-IgE therapy for allergic bronchopulmonary aspergillosis. J Microbiol Immunol Infect 49 (2016), 459–463.
177. Voskamp, A.L., Gillman, A., Symons, K., Sandrini, A., Rolland, J.M., O'Hehir, R.E., et al. Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract 3 (2015), 192–199.
178. El-Qutob, D., Off-label uses of omalizumab. Clin Rev Allergy Immunol 50 (2016), 84–96.
179. Cooper, P.J., Ayre, G., Martin, C., Rizzo, J.A., Ponte, E.V., Cruz, A.A., Geohelminth infections: a review of the role of IgE and assessment of potential risks of anti-IgE treatment. Allergy 63 (2008), 409–417.
180. Jarrett, E.E., Miller, H.R., Production and activities of IgE in helminth infection. Prog Allergy 31 (1982), 178–233.
181. Anthony, R.M., Rutitzky, L.I., Urban, J.F. Jr., Stadecker, M.J., Gause, W.C., Protective immune mechanisms in helminth infection. Nat Rev Immunol 7 (2007), 975–987.
182. Noga, O., Hanf, G., Brachmann, I., Klucken, A.C., Kleine-Tebbe, J., Rosseau, S., et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 117 (2006), 1493–1499.
183. Busse, W., Corren, J., Lanier, B.Q., McAlary, M., Fowler-Taylor, A., Cioppa, G.D., et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108 (2001), 184–190.
184. Buhl, R., Soler, M., Matz, J., Townley, R., O'Brien, J., Noga, O., et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 20 (2002), 73–78.
185. Lanier, B.Q., Corren, J., Lumry, W., Liu, J., Fowler-Taylor, A., Gupta, N., Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 91 (2003), 154–159.
186. Ayres, J.G., Higgins, B., Chilvers, E.R., Ayre, G., Blogg, M., Fox, H., Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 59 (2004), 701–708.
187. Vignola, A.M., Humbert, M., Bousquet, J., Boulet, L.P., Hedgecock, S., Blogg, M., et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 59 (2004), 709–717.
188. Humbert, M., Beasley, R., Ayres, J., Slavin, R., Hebert, J., Bousquet, J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60 (2005), 309–316.
189. Busse, W.W., Morgan, W.J., Gergen, P.J., Mitchell, H.E., Gern, J.E., Liu, A.H., et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 364 (2011), 1005–1015.
190. Casale, T.B., Bernstein, J.A., Maurer, M., Saini, S.S., Trzaskoma, B., Chen, H., et al. Similar efficacy with omalizumab in chronic idiopathic/spontaneous urticaria despite different background therapy. J Allergy Clin Immunol Pract, 3, 2015 743–50 e1.
191. Casale, T.B., Condemi, J., LaForce, C., Nayak, A., Rowe, M., Watrous, M., et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 286 (2001), 2956–2967.
192. Kuehr, J., Brauburger, J., Zielen, S., Schauer, U., Kamin, W., Von Berg, A., et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 109 (2002), 274–280.
193. Chervinsky, P., Casale, T., Townley, R., Tripathy, I., Hedgecock, S., Fowler-Taylor, A., et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 91 (2003), 160–167.
194. Kaplan, A., Ledford, D., Ashby, M., Canvin, J., Zazzali, J.L., Conner, E., et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 132 (2013), 101–109.
195. Long, A., Rahmaoui, A., Rothman, K.J., Guinan, E., Eisner, M., Bradley, M.S., et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol 134 (2014), 560–567 e4.
196. “Xolair” (omalizumab). Summary of product characteristics, June 2015, Novartis Pharma GmbH, Nuremberg, Germany.
197. Foroughi, S., Foster, B., Kim, N., Bernardino, L.B., Scott, L.M., Hamilton, R.G., et al. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol 120 (2007), 594–601.
198. Cruz, A.A., Lima, F., Sarinho, E., Ayre, G., Martin, C., Fox, H., et al. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy 37 (2007), 197–207.
199. Yalcin, A.D., Bisgin, A., Cetinkaya, R., Yildirim, M., Gorczynski, R.M., Clinical course and side effects of anti-IgE monoclonal antibody in patients with severe persistent asthma. Clin Lab 59 (2013), 71–77.
200. Skiepko, R., Zietkowski, Z., Skiepko, U., Tomasiak-Lozowska, M.M., Bodzenta-Lukaszyk, A., Echinococcus multilocularis infection in a patient treated with omalizumab. J Investig Allergol Clin Immunol 23 (2013), 199–200.
201. Frazer-Abel, A., Sepiashvili, L., Mbughuni, M.M., Willrich, M.A., Overview of laboratory testing and clinical presentations of complement deficiencies and dysregulation. Adv Clin Chem 77 (2016), 1–75.
202. Pettigrew, H.D., Teuber, S.S., Gershwin, M.E., Clinical significance of complement deficiencies. Ann N Y Acad Sci 1173 (2009), 108–123.
203. Reis, E.S., Mastellos, D.C., Yancopoulou, D., Risitano, A.M., Ricklin, D., Lambris, J.D., Applying complement therapeutics to rare diseases. Clin Immunol 161 (2015), 225–240.
204. Food and Drug Administration. Eculizumab Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM217725.pdf.
205. European Medicines Agency. Soliris: EPAR Product Information Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000791/WC500054208.pdf.
206. Devalet, B., Mullier, F., Chatelain, B., Dogne, J.M., Chatelain, C., Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review. Eur J Haematol 95 (2015), 190–198.
207. Helley, D., de Latour, R.P., Porcher, R., Rodrigues, C.A., Galy-Fauroux, I., Matheron, J., et al. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Haematologica 95 (2010), 574–581.
208. Weitz, I.C., Razavi, P., Rochanda, L., Zwicker, J., Furie, B., Manly, D., et al. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation. Thromb Res 130 (2012), 361–368.
209. Hillmen, P., Muus, P., Duhrsen, U., Risitano, A.M., Schubert, J., Luzzatto, L., et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 110 (2007), 4123–4128.
210. Brodsky, R.A., Young, N.S., Antonioli, E., Risitano, A.M., Schrezenmeier, H., Schubert, J., et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 111 (2008), 1840–1847.
211. Kelly, R.J., Hill, A., Arnold, L.M., Brooksbank, G.L., Richards, S.J., Cullen, M., et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 117 (2011), 6786–6792.
212. Zuber, J., Fakhouri, F., Roumenina, L.T., Loirat, C., Fremeaux-Bacchi, V., French Study Group for a HCG. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 8 (2012), 643–657.
213. Licht, C., Greenbaum, L.A., Muus, P., Babu, S., Bedrosian, C.L., Cohen, D.J., et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87 (2015), 1061–1073.
214. Zuber, J., Le Quintrec, M., Krid, S., Bertoye, C., Gueutin, V., Lahoche, A., et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 12 (2012), 3337–3354.
215. Matar, D., Naqvi, F., Racusen, L.C., Carter-Monroe, N., Montgomery, R.A., Alachkar, N., Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation 98 (2014), 1205–1212.
216. Johnson, C.K., Leca, N., Eculizumab use in kidney transplantation. Curr Opin Organ Transplant 20 (2015), 643–651.
217. Chua, J., Paizis, K., He, S.Z., Mount, P., Suspected atypical haemolytic uraemic syndrome in two post-partum patients with foetal-death in utero responding to eculizumab. Nephrology (Carlton) 22:Suppl. 1 (2017), 18–22.
218. Abe, T., Sasaki, A., Ueda, T., Miyakawa, Y., Ochiai, H., Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab: a case report. Medicine (Baltimore), 96, 2017, e6056.
219. Lapeyraque, A.L., Malina, M., Fremeaux-Bacchi, V., Boppel, T., Kirschfink, M., Oualha, M., et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 364 (2011), 2561–2563.
220. Cavero, T., Rabasco, C., Lopez, A., Roman, E., Avila, A., Sevillano, A., et al. Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrol Dial Transplant 32 (2017), 466–474.
221. Asif, A., Nayer, A., Haas, C.S., Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. J Nephrol 30 (2017), 347–362.
222. Elsallabi, O., Bhatt, V.R., Dhakal, P., Foster, K.W., Tendulkar, K.K., Hematopoietic stem cell transplant-associated thrombotic microangiopathy. Clin Appl Thromb Hemost 22 (2016), 12–20.
223. Bohl, S.R., Kuchenbauer, F., von Harsdorf, S., Kloevekorn, N., Schonsteiner, S.S., Rouhi, A., et al. Thrombotic microangiopathy after allogeneic stem cell transplantation – a comparison of eculizumab therapy and conventional therapy. Biol Blood Marrow Transplant 23 (2017), 2172–2177.
224. Morales, E., Rabasco, C., Gutierrez, E., Praga, M., A case of thrombotic micro-angiopathy after heart transplantation successfully treated with eculizumab. Transpl Int 28 (2015), 878–880.
225. Vasu, S., Wu, H., Satoskar, A., Puto, M., Roddy, J., Blum, W., et al. Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy. Bone Marrow Transplant 51 (2016), 1241–1244.
226. Bomback, A.S., Smith, R.J., Barile, G.R., Zhang, Y., Heher, E.C., Herlitz, L., et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 7 (2012), 748–756.
227. Mathern, D.R., Heeger, P.S., Molecules great and small: the complement system. Clin J Am Soc Nephrol 10 (2015), 1636–1650.
228. Eskandary, F., Wahrmann, M., Muhlbacher, J., Bohmig, G.A., Complement inhibition as potential new therapy for antibody-mediated rejection. Transpl Int 29 (2016), 392–402.
229. Burbach, M., Suberbielle, C., Brocheriou, I., Ridel, C., Mesnard, L., Dahan, K., et al. Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts. Transplantation 98 (2014), 1056–1059.
230. Bentall, A., Tyan, D.B., Sequeira, F., Everly, M.J., Gandhi, M.J., Cornell, L.D., et al. Antibody-mediated rejection despite inhibition of terminal complement. Transpl Int 27 (2014), 1235–1243.
231. Stegall, M.D., Diwan, T., Raghavaiah, S., Cornell, L.D., Burns, J., Dean, P.G., et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 11 (2011), 2405–2413.
232. Cornell, L.D., Schinstock, C.A., Gandhi, M.J., Kremers, W.K., Stegall, M.D., Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. Am J Transplant 15 (2015), 1293–1302.
233. Yehoshua, Z., de Amorim Garcia Filho, C.A., Nunes, R.P., Gregori, G., Penha, F.M., Moshfeghi, A.A., et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology 121 (2014), 693–701.
234. Dumas, G., Habibi, A., Onimus, T., Merle, J.C., Razazi, K., Mekontso Dessap, A., et al. Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients. Blood 127 (2016), 1062–1064.
235. Mevorach, D., Reiner, I., Grau, A., Ilan, U., Berkun, Y., Ta-Shma, A., et al. Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation. Ann Neurol 80 (2016), 708–717.
236. Smith, S.G., Watson, B., Clark, G., Gauvreau, G.M., Eculizumab for treatment of asthma. Expert Opin Biol Ther 12 (2012), 529–537.
237. Misawa, S., [Novel therapeutic interventions in Guillain–Barré syndrome: review and future perspective]. Brain Nerve 67 (2015), 1421–1428.
238. Pittock, S.J., Lennon, V.A., McKeon, A., Mandrekar, J., Weinshenker, B.G., Lucchinetti, C.F., et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 12 (2013), 554–562.
239. Howard, J.F. Jr., Barohn, R.J., Cutter, G.R., Freimer, M., Juel, V.C., Mozaffar, T., et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve 48 (2013), 76–84.
240. Pallares, D.E., Figueroa, J.E., Densen, P., Giclas, P.C., Marshall, G.S., Invasive Haemophilus influenzae type b infection in a child with familial deficiency of the β subunit of the eighth component of complement. J Pediatr 128 (1996), 102–103.
241. Del Rio, C., Stephens, D.S., Knapp, J.S., Rice, R.J., Schalla, W.O., Comparison of isolates of Neisseria gonorrhoeae causing meningitis and report of gonococcal meningitis in a patient with C8 deficiency. J Clin Microbiol 27 (1989), 1045–1049.
242. Cohn, A.C., MacNeil, J.R., Clark, T.A., Ortega-Sanchez, I.R., Briere, E.Z., Meissner, H.C., et al. Prevention and control of meningococcal disease: recommendations of the advisory Committee on immunization practices (ACIP). MMWR Recomm Rep 62 (2013), 1–28.
243. Bouts, A., Monnens, L., Davin, J.C., Struijk, G., Spanjaard, L., Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy. Pediatr Nephrol 26 (2011), 1919–1920.
244. Vicente, D., Esnal, O., Perez-Trallero, E., Fatal Neisseria meningitidis serogroup X sepsis in immunocompromised patients in Spain. Virulence of clinical isolates. J Infect 64 (2012), 184–187.
245. Struijk, G.H., Bouts, A.H., Rijkers, G.T., Kuin, E.A., ten Berge, I.J., Bemelman, F.J., Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. Am J Transplant 13 (2013), 819–820.
246. Rey-Mugica Mde, L., Hernando-Real, S., Carrero-Gonzalez, P., Queizan-Hernandez, J.A., [Meningococcemia during eculizumab treatment]. Enferm Infecc Microbiol Clin, 31, 2013, 62.
247. Applegate, A.O., Fong, V.C., Tardivel, K., Lippold, S.A., Zarate, S., Notes from the field: meningococcal disease in an international traveler on eculizumab therapy – United States. MMWR Morb Mortal Wkly Rep 2016:65 (2015), 696–697.
248. Hernando Real, S., Vega Castano, S., Pajares Garcia, R., Meningococcemia in vaccinated patient under treatment with eculizumab. Enferm Infecc Microbiol Clin 35 (2017), 200–201.
249. Friedl, C., Hackl, G., Schilcher, G., Rosenkranz, A.R., Eller, K., Eller, P., Waterhouse-Friderichsen syndrome due to Neisseria meningitidis infection in a young adult with thrombotic microangiopathy and eculizumab treatment: case report and review of management. Ann Hematol 96 (2017), 879–880.
250. Legendre, C.M., Licht, C., Muus, P., Greenbaum, L.A., Babu, S., Bedrosian, C., et al. Terminal complement inhibitor eculizumab in atypical hemolytic–uremic syndrome. N Engl J Med 368 (2013), 2169–2181.
251. Folaranmi, T., Rubin, L., Martin, S.W., Patel, M., MacNeil, J.R., Centers for Disease C. Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2015:64 (2015), 608–612.
252. Platonov, A.E., Vershinina, I.V., Kuijper, E.J., Borrow, R., Kayhty, H., Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine 21 (2003), 4437–4447.
253. Burrage, M., Robinson, A., Borrow, R., Andrews, N., Southern, J., Findlow, J., et al. Effect of vaccination with Carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun 70 (2002), 4946–4954.
254. Sikkema, D.J., Friedman, K.E., Corsaro, B., Kimura, A., Hildreth, S.W., Madore, D.V., et al. Relationship between serum bactericidal activity and serogroup-specific immunoglobulin G concentration for adults, toddlers, and infants immunized with Neisseria meningitidis serogroup C vaccines. Clin Diagn Lab Immunol 7 (2000), 764–768.
255. Cohn, A., MacNeil, J., The changing epidemiology of meningococcal disease. Infect Dis Clin North Am 29 (2015), 667–677.
256. Santolaya, M.E., O'Ryan, M., Valenzuela, M.T., Prado, V., Vergara, R.F., Munoz, A., et al. Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vaccin Immunother 9 (2013), 2304–2310.
257. Gleesing, J., Chiwane, S., Rongkavilit, C., Gonococcal septic shock associated with eculizumab treatment. Pediatr Infect Dis J, 31, 2012, 543.
258. Hublikar, S., Maher, W.E., Bazan, J.A., Disseminated gonococcal infection and eculizumab—a “high risk” connection?. Sex Transm Dis 41 (2014), 747–748.
259. Krid, S., Roumenina, L.T., Beury, D., Charbit, M., Boyer, O., Fremeaux-Bacchi, V., et al. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant 12 (2012), 1938–1944.
260. Patir, P., Isik, Y., Turk, Y., Ugur, M.C., Ceylan, C., Gorgun, G., et al. Necrotizing fasciitis in paroxysmal nocturnal hemoglobinuria. Case Rep Hematol, 2015, 2015, 908087.
261. Webb, B.J., Healy, R., Child, B., Majers, J., Anand, S., Gouw, L., Recurrent infection with Pseudomonas aeruginosa during eculizumab therapy in an allogeneic hematopoietic stem cell transplant recipient. Transpl Infect Dis 18 (2016), 312–314.
262. Stoermer, K.A., Morrison, T.E., Complement and viral pathogenesis. Virology 411 (2011), 362–373.
263. Borhan, W.M., Dababo, M.A., Thompson, L.D., Saleem, M., Pashley, N., Acute necrotizing herpetic tonsillitis: a report of two cases. Head Neck Pathol 9 (2015), 119–122.
264. Gomez-Cibeira, E., Ivanovic-Barbeito, Y., Gutierrez-Martinez, E., Morales, E., Abradelo, M., Hilario, A., et al. Eculizumab-related progressive multifocal leukoencephalopathy. Neurology 86 (2016), 399–400.
265. Speth, C., Rambach, G., Wurzner, R., Lass-Florl, C., Complement and fungal pathogens: an update. Mycoses 51 (2008), 477–496.
266. Vellanki, V.S., Bargman, J.M., Aspergillus niger peritonitis in a peritoneal dialysis patient treated with eculizumab. Ren Fail 36 (2014), 631–633.
267. Volokhina, E.B., van de Kar, N.C., Bergseth, G., van der Velden, T.J., Westra, D., Wetzels, J.F., et al. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clin Immunol 160 (2015), 237–243.
268. Jodele, S., Fukuda, T., Vinks, A., Mizuno, K., Laskin, B.L., Goebel, J., et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant 20 (2014), 518–525.
269. Jodele, S., Fukuda, T., Mizuno, K., Vinks, A.A., Laskin, B.L., Goebel, J., et al. Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 22 (2016), 307–315.
270. Peffault de Latour, R., Fremeaux-Bacchi, V., Porcher, R., Xhaard, A., Rosain, J., Castaneda, D.C., et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood 125 (2015), 775–783.